Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 14/20 | 0.47 |
| ▸ | THRA | P10827 | 12/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6516475 | 0.94 | THRA (0.46) | HTTSMN1; SMN2LMNAKDM4ETHRB | |
| SCHEMBL6510883 | 0.94 | SMN1; SMN2 (0.48) | HTTSMN1; SMN2LMNAKDM4ETHRB | |
| SCHEMBL6513939 | 0.92 | MAPT (0.51) | HTTSMN1; SMN2THRBTHRAMAPT | |
| SCHEMBL6520233 | 0.92 | THRB (0.56) | HTTSMN1; SMN2LMNAKDM4ETHRB | |
| SCHEMBL6521776 | 0.91 | THRB (0.50) | THRBTHRAMAPT | |
| SCHEMBL6860326 | 0.91 | SMN1; SMN2 (0.48) | HTTSMN1; SMN2LMNAKDM4ETHRB | |
| SCHEMBL6524629 | 0.91 | MAPT (0.55) | HTTSMN1; SMN2LMNAKDM4ETHRB | |
| SCHEMBL6520450 | 0.91 | MAPT (0.58) | HTTSMN1; SMN2KDM4ETHRBTHRA | |
| SCHEMBL6513235 | 0.90 | THRB (0.55) | HTTSMN1; SMN2LMNAKDM4ETHRB | |
| SCHEMBL6521727 | 0.90 | SMN1; SMN2 (0.51) | HTTSMN1; SMN2LMNAKDM4ETHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 2005-02-10 | — | — | US | disclosed |
| US-6794406-B2 | FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20030078288-A1 | Indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078288-A1 | Indole derivatives | IDO1, IDO2, TPH2 | HTT 399/4885SMN1; SMN2 4749/4885LMNA 3113/4885 |
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | HMGCR, CYP46A1, EBP | HTT 1524/4885SMN1; SMN2 4875/4885LMNA 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.